Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Evidence context Published methods answer population-level questions
4 Contextualizing Findings in a Competitive Landscape The comparison reflects increasing competition between oral GLP-1 therapies, particularly following the recent FDA approval of orforglipron for chronic weight management
We recommend consistent monitoring of new developments and guidance on this issue
This distinguishes it from better-known compounds such as semaglutide (Ozempic/Wegovy), which targets only the GLP-1 receptor, and from tirzepatide (Mounjaro/Zepbound), which is a dual GLP-1/GIP agonist
Int J Med Inform
US$ 25.47
US$ 25.67
US$ 28.88
US$ 28.28
US$ 21.18
US$ 28.33
